Conway Thomas P, Vu Bao Gia, Beattie Sarah R, Krysan Damian J, Moye-Rowley W Scott
Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Department of Pediatrics, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
mSphere. 2024 Dec 19;9(12):e0079224. doi: 10.1128/msphere.00792-24. Epub 2024 Nov 18.
Incidences of fluconazole (FLC) resistance among clinical isolates are a growing issue in clinics. The pleiotropic drug response network in confers azole resistance and is defined primarily by the ZnCys zinc cluster-containing transcription factor Pdr1 and target genes such as , which encodes an ATP-binding cassette transporter protein thought to act as an FLC efflux pump. Mutations in the gene that render the transcription factor hyperactive are the most common cause of fluconazole resistance among clinical isolates. The phenothiazine class drug fluphenazine and a molecular derivative, CWHM-974, which both exhibit antifungal properties, have been shown to induce the expression of Cdr1 in spp. We have used a firefly luciferase reporter gene driven by the promoter to demonstrate two distinct patterns of promoter activation kinetics: gradual promoter activation kinetics that occur in response to ergosterol limitations imposed by exposure to azole and polyene class antifungals and a robust and rapid induction occurring in response to the stress imposed by fluphenazines. We can attribute these different patterns of induction as proceeding through the promoter region of this gene since this is the only segment of the gene included in the luciferase reporter construct. Genetic analysis indicates that the signaling pathways responsible for phenothiazine and azole induction of overlap but are not identical. The short time course of phenothiazine induction suggests that these compounds may act more directly on the Pdr1 protein to stimulate its activity.
has emerged as the second-leading cause of candidiasis due, in part, to its ability to acquire high-level resistance to azole drugs, a major class of antifungal that acts to block the biosynthesis of the fungal sterol ergosterol. The presence of azole drugs causes the induction of a variety of genes involved in controlling susceptibility to this drug class, including drug transporters and ergosterol biosynthetic genes such as ERG11. We found that the presence of azole drugs leads to an induction of genes encoding drug transporters and ERG11, while exposure of cells to antifungals of the phenothiazine class of drugs caused a much faster and larger induction of drug transporters but not ERG11. Coupled with further genetic analyses of the effects of azole and phenothiazine drugs, our data indicate that these compounds are sensed and responded to differentially in the yeast cell.
临床分离株中氟康唑(FLC)耐药的发生率在临床上是一个日益严重的问题。中的多效药物反应网络赋予唑类耐药性,主要由含ZnCys锌簇的转录因子Pdr1和靶基因如定义,该基因编码一种ATP结合盒转运蛋白,被认为是一种FLC外排泵。使转录因子过度活跃的基因中的突变是临床分离株中氟康唑耐药的最常见原因。吩噻嗪类药物氟奋乃静和一种分子衍生物CWHM - 974都具有抗真菌特性,已被证明能诱导白色念珠菌中Cdr1的表达。我们使用了由Cdr1启动子驱动的萤火虫荧光素酶报告基因来证明Cdr1启动子激活动力学的两种不同模式:因暴露于唑类和多烯类抗真菌药物导致的麦角固醇限制而发生的逐渐启动子激活动力学,以及因氟奋乃静施加的应激而发生的强烈且快速的Cdr1诱导。我们可以将这些不同的Cdr1诱导模式归因于通过该基因的启动子区域进行,因为这是荧光素酶报告构建体中包含的该基因的唯一区段。遗传分析表明,负责吩噻嗪和唑类诱导Cdr1的信号通路重叠但不相同。吩噻嗪诱导的短时间进程表明这些化合物可能更直接作用于Pdr1蛋白以刺激其活性。
白色念珠菌已成为念珠菌病的第二大主要病因,部分原因是其能够获得对唑类药物的高水平耐药性,唑类药物是一类主要的抗真菌药物,作用是阻断真菌固醇麦角固醇的生物合成。唑类药物的存在会导致诱导多种参与控制对该类药物敏感性的基因,包括药物转运蛋白和麦角固醇生物合成基因如ERG11。我们发现唑类药物的存在会导致编码药物转运蛋白和ERG11的基因的诱导,而将白色念珠菌细胞暴露于吩噻嗪类药物的抗真菌剂会导致药物转运蛋白的诱导更快且更大,但不会诱导ERG11。结合对唑类和吩噻嗪类药物作用的进一步遗传分析,我们的数据表明这些化合物在酵母细胞中被不同地感知和响应。